• Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO
• Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company
• The appointment highlights Lexaria’s confidence in its recently confirmed focus on important GLP-1 studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial Officer (“CFO”). Nelson will lead Lexaria’s financial operations, mainly as it looks to double down on GLP-1 human clinical studies for the 2024 calendar year (https://ibn.fm/qIeLZ).

Nelson delivers over 15 years of corporate finance and operations experience within the life sciences industry. Having worked in key organizations such as Rain Oncology, Inc., a late-stage precision oncology biotech company, Lexaria’s management is confident that his skills will be of tremendous value to the company and its growth. Nelson has also served in various roles at Rigel Pharmaceuticals, Inc., including Vice President Finance. He was also a vital member of the executive team that developed and launched TAVALISSE(R) to treat chronic immune thrombocytopenia.

“Nelson’s deep financial leadership experience will be instrumental to the execution of Lexaria’s long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet needs,” noted Chris Bunka, Lexaria’s CEO.

This appointment follows Lexaria’s recent move to hire a contract research organization for its second GLP-1 human pilot study. The study will explore the company’s patented DehydraTECH(TM) technology for the improved delivery of glucagon-like peptide 1 (“GLP-1”) drugs used to treat type 2 diabetes and weight loss. Nelson will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company.

Nelson is optimistic about joining the company, citing DehydraTECH’s potential and proven track record.

“Lexaria has a significant opportunity in continuing its pursuit as a global innovator in drug delivery platforms as proven by the strong potential of DehydraTECH in GLP-1 and hypertension,” he noted. “I’m excited to join the team and look forward to contributing to the company’s progress in GLP-1 and other areas,” he added.

This appointment affirms Lexaria’s commitment to actualize the roadmap detailed earlier in the year, and its confidence in the direction it has taken to focus on GLP-1 studies.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Large corporations such as Walmart and Nordcell Group increasing renewable energy investments
• Turbo Energy offers commercial clients Sunbox Industry, an all-in-one solution that integrates inverters, lithium-ion batteries, and AI-powered software to reduce costs, increase efficiency, and protect against price shocks
• TURB’s AI-powered systems analyze consumption patterns, weather forecasts, and pricing trends to manage energy generation, increase efficiency, and optimize power output
• Turbo Community offers new clients opportunities to rent or finance systems, enables members with large photovoltaic installations to become energy producers and sell extra power

Walmart recently announced plans to significantly expand its renewable energy portfolio, aiming to add 1 GW of on-site clean energy and 2 GW of community-scale solar by 2030 (https://ibn.fm/wTj8x). In the EU, Nordcell Group recently unveiled plans to construct a 1.2 GW manufacturing facility in Sweden, driven by EU regulatory pressures and the growing demand for sustainable solar products (https://ibn.fm/sPOIC).

Turbo Energy (NASDAQ: TURB), a photovoltaic energy company based in Spain, offers energy storage and management solutions that align with this growing shift to renewable energy by commercial enterprises worldwide.

TURB’s Sunbox Industry is an advanced renewable energy solution integrating inverters, lithium-ion batteries, and AI-driven software for enhanced energy management. Powered by customizable features and real-time monitoring functionalities, Sunbox Industry streamlines energy usage, minimizes electricity expenses, and guarantees seamless power supply for commercial enterprises.

The demand for residential photovoltaic systems is also surging amid price shocks and political instability. TURB’s Sunbox Home helps homeowners advance the green transition while reducing expenses and achieving energy independence.

TURB’s solutions manage energy generation and consumption through an AI-driven approach. Both Sunbox Industry and Sunbox Home employ data-centric features that analyze consumption patterns, weather forecasts, and pricing trends to maximize energy generation, increase efficiency, and optimize power output.

Turbo Energy is committed to powering the global shift towards cleaner, sustainable energy sources. The Turbo Community is an integral part of the company’s strategy, enabling clients with large photovoltaic installations to become energy producers by selling extra power on the market. The Turbo Community additionally helps new businesses make the shift with opportunities to rent or finance solar energy systems.

With an eye on international expansion, Turbo Energy recently listed on the NASDAQ under the symbol TURB with plans to advance product development and expand its target market. Initially, the company intends to enter North and South America with a focus on advancing its technology and acquiring new talent.

“Our NASDAQ debut is just the beginning of an exciting chapter of growth and evolution,” said Turbo Energy CEO Mariano Soria (https://ibn.fm/7OTPx). “We are determined to attract the best talent, drive innovation, and expand our global reach to continue to be a leader in the energy revolution.”

Turbo Energy was incorporated in 2013 and operates as a subsidiary of Umbrella Solar Investment S.A. in Valencia, Spain. With a comprehensive range of cutting-edge solutions tailored for residential and commercial users, the company is strongly positioned to grow as the world shifts to cleaner, more sustainable energy sources.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

• The streaming market is undergoing significant changes, with observers noting that the future of streaming is clearly being driven by the vast market opportunity it presents, with free ad-supported streaming platforms currently being the fastest-growing segment of the streaming business
• Bravo Multinational, a company forging a solid foundation through streaming media and technology, is looking to tap into this fast-growing market segment
• Bravo finalized the acquisition of the TVee NOW(TM) over-the-top (“OTT”) streaming platform, provided the company with the technology and music library streaming rights to offer content at no cost to the viewer
• Following the acquisition, Bravo now owns cutting-edge OTT streaming technology and is deploying a model that blends advertising-based video-on-demand (“AVOD”) and subscription-based video-on-demand (“SVOD”) services

For many years, the TV industry was segmented into production (studios), distribution (TV channels that aired the content), and platform (the cable TV and satellite providers that enabled the TV channels to air their content). However, this traditional model has been dismantled over the past two and a half decades thanks to rapid vertical consolidation. Today, streaming services produce, distribute, and provide a platform for their content. Traditional TV channels and production companies like Disney, Paramount, and NBC have not been left behind, and have entered the streaming space, with this move reducing or eliminating their heretofore reliance on cable TV and satellite providers (https://ibn.fm/kudFV).

Many consider video streaming one of the biggest drivers of transformation in the entertainment industry today. It has created a massive demand for content and brought more TV shows and movies and other content directly into our homes than ever before. Consumers have responded in kind, subscribing to more services to keep up with new releases. A recent Forbes Home survey, for instance, shows that 95% of Americans now pay for more than one streaming service, up from 86% in 2023 (https://ibn.fm/A1WgO).

However, despite this growth, most big-name streaming services are growing at a slower rate than before, with observers attributing this slow-down to the fact that the streamers have reached most of their possible audience. “The golden age of high-flying, big-spending streaming seems to be over. In its place, there’s a new thing booming in streaming. Free ad-supported platforms are the fastest-growing part of the streaming business right now,” reads an article in The Verge titled “The future of streaming is ads.” The article posits that this segment is “only going to get bigger from here” (https://ibn.fm/gNIsB).

Looking to tap into this expected growth is Bravo Multinational (OTC: BRVO), a company forging a solid foundation through streaming media and technology. Bravo finalized the acquisition of certain streaming assets of Streaming TVEE, Inc., including the TVee NOW(TM) streaming platform, which delivers content directly to users via the internet. The beta version of TVee NOW(TM) launched in Q1 2024.

The acquisition enabled Bravo to own cutting-edge, over-the-top (“OTT”) streaming technology, allowing it to deploy a hybrid model that blends advertising-based video-on-demand (“AVOD”) and subscription-based video-on-demand (“SVOD”) services. It also provided Bravo with the technology and music library streaming rights to offer content such as linear TV (traditional broadcast TV) and an array of free on-demand content, including but not limited to movies, series, shows, concerts, comedy specials, events, and more. Bravo is nonetheless also looking to form partnerships with Free Ad-Supported Streaming Television (“FAST”) channels to enrich its platform with even more content.

AVOD and FAST are the two types of free streaming services. A FAST service is characterized by programmed always-on streaming channels that run 24/7 and include ads, while an AVOD service gives you access to a library of on-demand content and features ads. Both AVOD and FAST are expected to feature prominently in the future of streaming, given that the “future of TV is free, it has ads, and it involves a lot of channel surfing,” according to The Verge article.

Supporting this assertion is a Deloitte survey that found that 59% of users of streaming services in the United States watch AVOD video streaming services that are either discounted or free. The survey also found that 44% of people had canceled at least one paid service in the previous half a year (https://ibn.fm/fWXRO). In addition, decisions by the likes of Netflix, Peacock, and Disney Plus, which previously were SVOD-only services, to add an ad-supported plan further give color to the assessment that the future of streaming is ads.

Against this backdrop, Bravo’s move to acquire and subsequently launch TVee NOW is advantageous on multiple fronts: it enables the company to tap into the growth projected within the various segments of the streaming market. In its market analysis report, for instance, Omdia noted that FAST channel revenue rose about 20x between 2019 and 2022 and is expected to triple between 2022 and 2027 to reach $12 billion (https://ibn.fm/6Ldkv).

Statista separately projects that the global AVOD market will achieve a revenue of $48.32 billion by 2024. It is expected to grow further by a CAGR of 9.53%, reaching $63.50 billion by 2027 (https://ibn.fm/xxMwk). The SVOD market is expected to grow from $108.5 billion in 2024 to $137.7 billion by 2027, representing a CAGR of 8.27% (https://ibn.fm/Qixxc), while OTT revenue is expected to grow from $154 billion in 2022 to $215 billion by 2029 (https://ibn.fm/ce2Df).

For more information, visit the company’s website at www.BravoMultinationalInc.com.

NOTE TO INVESTORS: The latest news and updates relating to BRVO are available in the company’s newsroom at https://ibn.fm/BRVO

• Correlate Energy Corp. is a distributed energy solutions company focused on solar energy installation opportunities as well as other clean energy infrastructure improvements
• Federal government incentives as well as decreasing costs of solar installation are helping to scale clean energy adoption across the United States
• Correlate Energy’s projects tend to take about a year from initial contact to completion, as exemplified by recently completed and commissioned contracts with American Tire Distributors and Continental Envelope for rooftop solar projects
• The company’s average contract size is about $2 million, and CIPI currently has about $150 million of in-progress projects in various stages of development

A Reuters report this month notes that the United States has doubled the pace of cutting carbon emissions through the efforts of solar, wind and energy storage projects since the passage of the federal clean energy investment Inflation Reduction Act (“IRA”) in 2022, while hydrogen, electric vehicle charging station, nuclear energy and geothermal projects have struggled to take advantage of the law’s funding opportunities (https://ibn.fm/r6i1X).

Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is enjoying an increase in profitable opportunities as it focuses its infrastructure know-how on setting up solar projects for corporate clients ready to build on the IRA’s benefits.

“We have a constant conveyor belt of a maturity of opportunities which allow us to smartly invest in different parts of the business,” Correlate Energy President and CEO Todd Michaels was quoted as saying in a recent Yahoo! Finance article (https://ibn.fm/3L3Qx). “Solar is the most applicable tech right now. It’s beating the grid for cost. You can easily do a 10% to 20% discount of what a person pays the local utility.”

CIPI’s most recent project announcements include an up-to-40 MW microgrid project outside of the Los Angeles metro area for a customer representing one of California’s largest privately owned oil and gas corporations (https://ibn.fm/ErXOz) and a 3.8 MW solar energy installation project (later expanded to 5.2 MW) for Pennsylvania-based stored energy solutions company EnerSys (https://ibn.fm/Se6Yk).

CIPI has also recently completed and commissioned already in the pipeline rooftop solar energy systems for American Tire Distributors’ headquarters in North Carolina (https://ibn.fm/vHDFf) and for Continental Envelope’s manufacturing plant in Illinois (https://ibn.fm/vGLTU).

“You have these proven businesses that are super well run that are looking for every edge to reduce cost and improve margin,” Michaels told Proactive Investors during a December interview (https://ibn.fm/pIej5). “Our average contract size today is about $2 million. … We typically work with customers like that that have, let’s say, 10 to 100 locations across the country, so it’s not usually just the one-off small, private business. It’s typically a portfolio business that has multiple operations.”

Correlate started with three people in January 2022 and has since begun to scale the business into additional markets with increased staff on the operations team and the revenue that comes in from its completed projects.

“It’s been all about executing on what we had in ’22 and setting ourselves up for doubling again, tripling again in the coming year,” Michaels said in December. “We have about $150 million of immediately actual projects that are (in) various stages of … development. About $22 million of those are, currently like, people are literally out there deployed onsite getting these projects completed. We have about another $50 million of projects that are fully contracted, that are mobilizing — they’re typically waiting for a utility approval, some permit, or are waiting for next summer to build versus building them in a place where we might be doing wintertime issues. So those are kind of the ready-to-go projects.”

The tax credit opportunities and the decreasing cost of solar installation are helping to drive Correlate’s growth. Installing solar panels costs (on average) about $2.86 per watt before taking advantage of available incentives, which is more than 65 percent cheaper than the $8.50 per watt price tag in 2010 (https://ibn.fm/r6rya).

For more information, visit the company’s website at www.Correlate.Energy, including the following:
Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income:  www.Correlate.Energy/our-process
Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program 

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

Podfest Multimedia Expo’s 2024 Masterclass will provide education on A.I. & Creator Tools over April 19th, 22nd, 23rd, and 24th. Taking place online, the four-day event brings the latest technological revolution directly to attendees’ screens with case studies, How To’s, and breakout sessions with cutting edge topics. The virtual summit will benefit audio and video creators at all levels, whether beginner, intermediate, or advanced. The AI & Creator Tools program has been designed to help its attendees stay ahead of the game in content creation.

Over the four days of the event, education will include sessions such as, “Teach ChatGPT to Respond Like You,” “AI/Automation Workflows for Video Podcasters,” “How to Use AI to Create Content You Own Without Being Sued,” and “5 ChatGPT Prompts to Turn Your Podcast Transcript Into Engaging Marketing Messages,” to name just a few. The full session schedule has just been released and is packed with not only education but even opportunities for networking and virtual visits with exhibitors!

With AI and related creator tools evolving almost daily, it has become crucial for members of the podcast community to continually learn in order to stay on top of the podcast process. Dramatic efficiencies are now available with the latest AI tools, providing an easier workflow, and thus allowing room for more creativity, on the way to making episodes more meaningful to listeners, setting them up to keep coming back for more.

Podfest Multimedia Expo brings together a community of people anxious to share valuable ideas and content with an expanding world, serving experienced or aspiring podcasters supporting one another through information exchange and education, and invaluable networking. Podfest Expo is an important member of your podcast team.

Registration information is as follows:

Categories Of Passes:

• Creator Pass: $49.00+$5.13 Fee

This entry ticket access includes: Every session LIVE during the event on April 19, 22-24

Does not include: Premium Sessions – Lifetime Access to Podfest Masterclass Recordings

• VIP (Creator + Lifetime Recordings): $149.00+$11.83 Fee

This entry ticket access includes: Access to All Tracks at Podfest Masterclass and lifetime recordings of every track Everything with Creator Pass – All recordings of the entire event with every session

Does not include: Access to Premium Sessions

• Premium (VIP + High Level Education): $249.00+$18.54 Fee

This entry ticket access includes: Everything included with the VIP Pass Recordings of the Premium Sessions AMA (ask me anything) and Exclusive Networking with Industry experts Includes a Pay-it-Forward Creator Level pass for someone less fortunate

• Speaker Pass (Only for confirmed speakers): $99.00+$8.48 Fee

This entry ticket access includes: Everything with Creator Pass Access to the LIVE Premium Sessions Your own recorded session Branded graphics.

Does not include: Lifetime Recordings of the whole event.

The Podfest Masterclass 2024 is being held as a virtual event, and brings powerful speakers to the Podfest forum to engage, teach, and spread awareness among enthusiasts globally. The speakers are influential people from their respective fields and include dignitaries, influencers, and thought leaders.

To learn more, visit https://podfestexpo.com/masterclass/.

• Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients
• AVERSA technology can be incorporated into any transdermal patch
• The company has a broad intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico and Australia
• Nutriband announced in March 2024 that it will submit a New Drug Application to the FDA seeking approval to market AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch
• In April 2024, the company announced it had received a contract manufacturing order from Fit For Life Group, with a supplier agreement to follow

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (“ADHD”). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• Developed under Lavish Entertainment, a wholly owned subsidiary of GTVH, Destino Ranch will be a one-of-a-kind destination that revolutionizes the concept of an immersive music and art venue.
• Phase one development begins after the execution of a land-use-and-development agreement outlining exclusive rights to purchase, use and operate the nearly 70-acre property. Additional upgrades on the initial property secured will “dramatically increase speed into the market.”
• Marco Moreno has been appointed as president of Lavish Entertainment to spearhead the development of Destino Ranch. Mr. Moreno has notable experience in the large-scale event development industry with high-fidelity collaborations through his company ABI Create.

Two months ago, Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, announced plans to develop a one-of-a-kind immersive entertainment venue (https://ibn.fm/1gHcL). In the past few weeks, GTVH and Lavish have made significant progress in transforming into reality the vision for the premier destination for year-round, world-class music, entertainment and art.

“The development of Destino Ranch ushers in a new and beyond-amazing chapter for Lavish Entertainment,” said Steffan Dalsgaard, CEO of GTV and founder of Lavish Entertainment. The companies “truly believe this flagship project will be a one-of-a-kind location and resort that revolutionizes what people think of as a music and art venue. Our plan is to develop a world-renowned destination that offers a superior level of amenities, services, exhibits and attractions, along with so much more than just a festival ground.”

Since the announcement of Destino Ranch, a planned 638-acre property conveniently located within a short drive from large population centers such as Phoenix, Los Angeles and Las Vegas, Lavish Entertainment has officially activated the first phase of development (https://ibn.fm/2h4IH). This phase includes the execution of a land-use-and-development agreement outlining exclusive rights to use and operate on the property.

Phase one development will focus on developing the first nearly 70-acres of land that already has in place substantial infrastructure features, such as special-event permits, graded roads, fencing, storage, septic, solar, landscaping, and water and irrigation rights. Further development in phase one will include site event plans and permitting, site prep and cleanout, staff infrastructure and housing, a temporary power grid, and event features and infrastructure.

In addition, last month Lavish Entertainment announced that it has executed a purchase agreement to acquire this first, nearly-70 acres of land that the company recently secured, which is prime and improved property for the Destino project (https://ibn.fm/WyV4R). The company noted that the upgrades were valued at nearly $6 million, which “has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.”

Lavish Entertainment president Marco Moreno stated: “With a strong background of delivering high-fidelity productions to notable large-scale installations such as EDC and the Super Bowl, Destino Ranch is the culmination of more than a decade of experience in the planning and execution of large-scale event projects and production. Our goal is to provide guests with memorable and life-changing experiences that captivate their minds for years to come. As we anticipate Destino Ranch becoming a globally renowned attraction, we are proud to showcase the launch of this project and look forward to sharing more exciting developments with our shareholders in the weeks ahead.”

For more information, visit www.GoldenTriangleInc.com and www.DestinoRanch.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• Bebuzee in November 2023 announced completion of its superapp, which combines multiple digital services into a single, user-friendly platform for the U.S. and European markets
• In September 2022, the company filed with the SEC for a Regulation A registration exempt public offering of up to $75 million of its common shares
• The company in April 2022 announced a private placement offering of up to $10 million of its common shares

Bebuzee (OTC: BBUZ), formerly Engage Mobility Inc., is a social platform and streaming service focused on development and deployment of America’s first superapp. The superapp will allow members to watch a wide variety of content, such as movies, series, documentaries and talk shows, on any internet-connected device.

Bebuzee’s technology scans the world’s news, features and information-flow to give its dedicated readers the best of the internet in one place – a one-stop platform for breaking news, interesting and important blogs, videos and photos.

The core features of the superapp include video streaming; photo sharing; Bebuzee Messaging service, which allows users to send text and voice messages and make voice and video calls; Shortbuz, used to make a variety of short-form entertaining videos; Blogbuz, a resource for people without time to scavenge the internet and other sources for news and information; Properbuz global real estate search; global tradesmen search; location reviews of neighborhoods, cities and even regions to help others find their ideal rental or real estate purchase; ShoppingBuz, a unique technology-driven e-commerce platform which gives merchants incredible tools to sell their products; Bebuzee Pay, a mobile payment and digital wallet service that allows users to make mobile payments and online transactions; TravelBuz, an online travel booking service; EventBuz, a ticket exchange and resale platform; and FlightBuz, a flight search engine.

The company is headquartered in Miami.

Introducing the Superapp to Western Markets

A superapp is a mobile phone app that offers a wide range of services within a single platform. This technology allows users to access various services without downloading and switching between multiple apps.

While superapps are popular in many parts of the world, including Latin America, Africa, the Middle East, Asia and Russia, they have achieved little adoption in Western markets. Perhaps the most widely known superapp is WeChat, which is estimated to have as many as 1.24 billion users, mostly in China.

Bebuzee aims to be the first developer to introduce and grow to widespread popularity a superapp in the U.S. and Europe. It took a strong step toward achieving this goal during the COVID-19 pandemic, when Bebuzee’s user base surged by 78% with over 42 million new users.

Whereas most social platforms are generic and only local postings make them somewhat relevant to local communities, Bebuzee has localized its platform for most countries by providing local content, entertainment and information that is frequently updated and refreshed.

The company says the average age of its superapp users is 39, with female users making up 62.8% of its user base. Its monetization strategy includes sales of video advertising, sponsored posts, banner ads and premium listings, as well as promotion of featured brands and property listings.

Market Opportunity

A report from Allied Market Research, a global market research, consulting and advisory firm, estimated that the worldwide superapps market was valued at $58.6 billion in 2022. The report projects the market to expand to $722.4 billion by 2032, growing at a CAGR of 28.9% for the forecast period.

The report identifies a few of the most popular superapps as Rappi in Latin America, Snapp in Iran, Line in Japan and Yandex Go in Russia and Kazakhstan.

Increasing adoption of mobile services and growing advancements in digital technologies are driving the growth of this market. In addition, a rise in government support for promoting the use of superapps is lending to expansion, according to the report.

Integration of blockchain technology in superapps is likewise anticipated to provide numerous opportunities for the expansion of the market during the forecast period, the report states.

Management Team

Joseph Onyero is Founder and CEO of Bebuzee. He has a background of managing multiple products from ideation to market launch and profitable monetization and has been building commercial web presences since 2005. He has worked as a Chief Marketing Officer and in business development. He previously owned and operated a travel and tourism company. He began in 2005 working on the concept and features that have evolved into the Bebuzee suite. He has grown Bebuzee from a living room start-up into a U.S. publicly traded company.

Claudia S. Spagnuolo is Chief Operating Officer at Bebuzee. She began with the company in 2014 as a user experience manager before being promoted to CMO in 2017. She previously worked as an assistant marketing director at the National Secretariat of the union CISL in Italy. Prior to that, she also worked as a researcher at the Complutense University of Madrid on issues of corporate management. She speaks three languages and holds a bachelor’s in political science and a master’s in administration from the University of Perugia in Italy.

For more information, visit the company’s website at www.Bebuzee.com.

NOTE TO INVESTORS: The latest news and updates relating to BBUZ are available in the company’s newsroom at https://ibn.fm/BBUZ

• SenesTech, a company that offers fertility control products for rodent pests, launched Evolve(TM) Soft Bait in October 2023, and has so far inked multiple distribution agreements as part of its multi-prong go-to-market strategy for the product
• The company recently announced it had signed a distribution agreement with Wilco Distributors Inc., a Glendale, Arizona-based distributor of pest management baits and tools to the rodent pest management market
• In addition to Evolve, SenesTech also offers ContraPest(R), a highly palatable professional-grade contraceptive liquid formulation for both male and female rats
• Evolve and ContraPest are positioned as effective non-lethal alternatives to registered rodenticides that can pose a danger to other animals

Committed to the sustainable, humane treatment of animals, SenesTech (NASDAQ: SNES) offers a one-of-a-kind technology for managing rat pest populations through safe fertility control. The company’s first product, ContraPest(R), is a highly palatable professional-grade contraceptive liquid formulation that targets the reproductive capabilities of both male and female rats to reduce their fertility. While ContraPest works, SenesTech observed that its liquid nature does not meet all customer/business preferences.

This led to the introduction in October 2023 of the non-liquid Evolve(TM) Soft Bait, which has similar efficacy to ContraPest but is in a solid form that is better accepted by the pest control industry, according to Joel Fruendt, SenesTech’s President and CEO (https://ibn.fm/pddhC). In addition, Evolve has a long shelf life, is easy to use, and is available at an excellent price point. Since October, SenesTech has implemented a multi-prong go-to-market strategy for Evolve, which has seen the company sell the new innovative product to customers through e-commerce platforms, its in-house direct sales team, and distributors.

SenesTech has so far inked multiple distribution agreements with many new and significant partners, helping the company get Evolve into the marketplace in the United States and abroad. Recently, the company signed a distribution agreement with Wilco Distributors Inc., a Glendale, Arizona-based family-owned distributor of pest management baits and tools to the rodent pest management market. Under the terms of the agreement, Wilco Distributors will be a stocking distributor for Evolve. Wilco Distributors has already placed its initial multi-pallet stocking order (https://ibn.fm/MLvtR).

“We are particularly pleased to be partnering with Wilco Distributors, as they have a clear commitment to finding innovative and responsible products for rodent pest management and a strong position in the agriculture space,” said Fruendt of the signed distribution agreement and SenesTech’s new partner.

Wilco Distributors’ President Blake Hazen commented on the partnership with SenesTech, saying, “Our mission is to manufacture and distribute quality rodent control products, both for homeowners and professionals, providing effective and efficient solutions and excellent customer service. SenesTech’s fertility control products fit extremely well into our portfolio, and we are excited to introduce our customers to Evolve and ContraPest. We already have products in stock and we are fulfilling initial orders.”

Numerous independent studies have shown that the active ingredients in ContraPest and Evolve, which are specifically formulated for rats and break down in their digestive systems, effectively reduce fertility in rodents. In this regard, ContraPest and Evolve can help control the rapid reproduction of rats, which, if left unchecked, can lead to overpopulation. A 2017 study puts this into perspective: a pair of rats can produce 500 million descendants in just three years (https://ibn.fm/zHOTN).

Given their unique capabilities and properties, ContraPest and Evolve are well positioned as more effective alternatives to registered rodenticides and poisons, which are linked to adverse effects. Rodenticides and poisons are known to move through the food chain when non-target animals prey on the poisoned rodents. This results in secondary and sometimes tertiary poisoning of other animals, leading to their deaths (https://ibn.fm/kffSe). Such adverse results have forced regulators to act, with states around the country sanctioning stricter regulations on commonly used poisons. For instance, last year, California Governor Gavin Newsom signed a bill that offered greater protections against rodenticides (https://ibn.fm/7lCbr). These developments have incentivized pest managers to look elsewhere.

“Pest management professionals and homeowners are seeking alternatives to traditional lethal methods and poisons, as poisons are highly regulated and are tricky to use without contamination, and traps are expensive and time-consuming to maintain,” conveyed Fruendt. “There is strong evidence that the addition of fertility control to an integrated pest management program increases efficacy and reduces the reliance on poison.”

SenesTech expects to capitalize on its product’s contraceptive capabilities to tap into the rodent pest control market, which represents a significant opportunity. Analysts at Straits Research project that the market will grow at a CAGR of 6.19% between 2023 and 2031, reaching an estimated $4.91 billion by 2031 from $2.86 billion in 2022 (https://ibn.fm/VHvEv).

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially “reversing the clock” on what would be considered healthy aging
• CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function
• Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast

In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function. The potential of this drug to treat multiple neurological diseases was highlighted during the latest episode of the “First In Human” podcast, hosted by Vial’s Executive Vice President of CRO Operations, Rich McCormick, featuring Clene’s CEO, Rob Etherington (https://ibn.fm/7eCrw).

Etherington, who has nearly 32 years of experience in pharmaceutical drug development, discussed the journey of CNM-Au8 from its conception to the promising results of clinical trials. These trials have demonstrated the drug’s potential to significantly enhance neurological functions, offering new hope to individuals battling Amyotrophic Lateral Sclerosis (“ALS”) and Multiple Sclerosis (“MS”).

The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity necessary for movement, cognitive function, and more. Etherington highlighted that CNM-Au8 is tailored to address the central nervous system’s needs, targeting diseases like ALS and MS.

“For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my brain,” Etherington said. “We had the idea to do that with a catalytically active nanotherapeutic suspension, which the patients drink daily.”

Clinical trials of CNM-Au8 have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially “reversing the clock” on what would be considered healthy aging. This breakthrough has the potential to significantly improve survival and quality of life for patients with neurodegenerative diseases, offering improvements in movement, speech, and overall function.

One of the key differences of CNM-Au8 is its oral consumption method, providing an easily accessible treatment option for patients. Its strong safety profile, without a single reported serious adverse event related to the drug, positions CNM-Au8 as a revolutionary treatment that can be administered alongside standard of care.

Clene’s commitment to addressing neurodegenerative diseases aligns with the urgent need for therapeutic breakthroughs in this field. The World Health Organization has predicted that neurodegenerative disease will become the second most prevalent cause of death within the next 20 years, making innovations like CNM-Au8 critical.

The development of CNM-Au8 has not been without challenges, including the complexity of creating a nanotherapeutic with medicinal efficacy and navigating regulatory pathways. Despite these hurdles, Clene has emerged as a leader in the field, with CNM-Au8 showing promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function.

Etherington also highlighted Clene’s collaborative efforts, including partnerships with academic centers of excellence and a significant grant from the National Institutes of Health. These collaborations have been instrumental in advancing the development of CNM-Au8 and understanding its mechanisms.

Looking ahead, Clene Inc. aims to transform healthcare for individuals with neurodegenerative diseases through CNM-Au8. The company is working towards regulatory approvals to bring this groundbreaking treatment to market. With its potential to improve mitochondrial function and enhance patient outcomes, CNM-Au8 represents a pioneering approach to treating neurodegenerative diseases.

To listen to the full podcast, visit https://ibn.fm/bTX5J.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN